Loading
AMEXHealthcareMedical - Devices
Latest quote
$2.665
−$0.045 · -1.66%
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
Regular session
$2.675
−$0.035 · -1.29%
Regular session · ET · Market data may be delayed.
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
Day range
Current $2.675
52-week range
Current $2.675
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
14
Overpriced
Sentiment
48
Mixed
Risk
75
High Risk
Momentum
34
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
Day range
Current $2.675
52-week range
Current $2.675
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | 1.45M USD | 1.43M USD | 5.42M USD | 10.8M USD |
| Cost of goods sold | — | 2.31M USD | — | 3.05M USD | 6.18M USD |
| Gross profit | — | −852K USD | 1.43M USD | 2.37M USD | 4.62M USD |
| Research and development | 84.22M USD | 39.33M USD | 21.31M USD | 1.81M USD | 2.58M USD |
| Selling, general, and administrative | 30.23M USD | 26.61M USD | 21.06M USD | 9.35M USD | 9.43M USD |
| Operating expenses | 113.56M USD | 65.94M USD | 42.38M USD | 11.47M USD | 12.01M USD |
| Interest income | 8.11M USD | 10.52M USD | 934K USD | 1.12M USD | 119K USD |
| Interest expense | 376K USD | 48K USD | 84K USD | — | — |
| Depreciation and amortization | 3.25M USD | 2.31M USD | 986K USD | 324K USD | 248K USD |
| Operating income | −113.56M USD | −66.8M USD | −40.94M USD | −9.1M USD | −7.39M USD |
| Net income | −103.12M USD | −79.28M USD | −46.51M USD | −10.76M USD | −7.27M USD |
Company facts updated Oct 9, 2026.
Third-party consensus; not a GoAI recommendation.
Average target
$11.00
311.21% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI10.47M0.00%2.3T USD0.03%$382.06+0.66%
iShares Russell 2000 ETFIWM7.33M0.01%77.7B USD0.19%$279.23+0.60%
Vanguard Extended Market ETFVXF3.12M0.00%95.4B USD0.05%$235.16+0.87%
iShares Russell 2000 Value ETFIWN2.63M0.02%13.75B USD0.24%$211.11+0.08%
iShares Biotechnology ETFIBB1.89M0.02%10.41B USD0.44%$206.28+2.89%
Vanguard Russell 2000 ETFVTWO1.87M0.01%18B USD0.06%$112.79+0.61%
Dimensional - US Small Cap ETFDFAS1.47M0.00%33.8B USD0.31%$78.465+0.47%
Schwab U.S. Small-Cap ETFSCHA1.14M0.01%21.73B USD0.03%$32.84+0.55%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWODimensional - US Small Cap ETFDFASSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
